Friday, May 27, 2016 11:01:04 AM
I'm still not sure either way, but I tend to believe mike41, with his apparent industry experience."
Obviously you're free to feel that way. I was not commenting on his experience but rather his willingness to reach certain conclusions based on facts that he does not have.
"If NNVC sublicenses on very generous terms"
"This would be important if NNVC sublicenses out to big pharma"
From the License: "Nano may not assign its rights and obligations under this Agreement without the written consent of the other parties hereto."
A sublicense would be an assignment of Nano's rights and obligations. TheraCour might be expected to be amenable to that and sign off on it, but not necessarily under the same terms originally extended to Nano.
"I'm still not sure if it's 15% of NNVCs take (CEO indication) or 15% of total sales (seems to be the language in the license). This would be important if NNVC sublicenses out to big pharma and keeps only a cut of sales, say 20-50%."
I'm not sure where the "CEO indication" comes from or what it means and frankly don't care much...the license is the license and it says "15% on its (Nano's) net sales". Any postulated sublicensing could be expected to lead to a new agreement and new terms.
"So if NNVC developed some manufacturing know-how, they would apparently own it and Theracour could use it." That's what it says.
"If Theracour develops it for NNVC's behalf and NNVC pays for it, does Theracour still own it?"
That's what I've been saying. The difference, which I thought was covered under "I understand your point now" but now seems not to be, is that NNVC is paying TheraCour and TheraCour personnel are developing products and processes for NNVC...that DOES NOT make it NNVC's IP.
We shouldn't be continuing to ignore the very important distinction between IP owner and licensee, but if we do then this confusion will persist. This isn't about how well the math may or may not work out. It's about what the NNVC shareholders can lay claim to as assets and what they can't.
"Successful commercialization is succeeding in the process of
commercializing. It is not successfully having commercialized."
Say what?
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM